A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2

Trial Profile

A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Eribulin (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Adenocarcinoma; Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 07 Jun 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018.
    • 12 Dec 2015 Interim results presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top